File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Isoniazid-induced gynaecomastia: report of a paediatric case and review of literature

TitleIsoniazid-induced gynaecomastia: report of a paediatric case and review of literature
Authors
KeywordsGynaecomastia
Isoniazid
Paediatric
Issue Date2020
Citation
BMC Endocrine Disorders, 2020, v. 20, n. 1, article no. 160 How to Cite?
AbstractBackground: Gynaecomastia is a fairly common condition in puberty but is rare in prepubertal boys. While it is necessary to exclude possible endocrinopathay in prepubertal gynaecomastia, medication is an important and potentially reversible cause to consider in new onset gynaecomastia. Isoniazid-induced gynaecomastia has been reported in adult males, but none was reported in the paediatric population and general paediatricians may not be aware of this uncommon side effect. Case presentation: We hereby report a 11-year-old prepubertal boy who developed gynaecomastia while taking anti-tuberculosis drugs. Investigations excluded endocrinopathies. Gynaecomastia subsided 8 weeks after stopping isoniazid. Conclusion: This case is the first paediatric case report describing the association of gynaecomastia with isoniazid use. It is important for general paediatricians to recognize this entity, as prompt diagnosis and cessation of the offending drug can lead to resolution of the problem.
Persistent Identifierhttp://hdl.handle.net/10722/352213

 

DC FieldValueLanguage
dc.contributor.authorPoon, Sarah Wing Yiu-
dc.contributor.authorSiu, Ka Ka-
dc.contributor.authorTsang, Anita Man Ching-
dc.date.accessioned2024-12-16T03:57:21Z-
dc.date.available2024-12-16T03:57:21Z-
dc.date.issued2020-
dc.identifier.citationBMC Endocrine Disorders, 2020, v. 20, n. 1, article no. 160-
dc.identifier.urihttp://hdl.handle.net/10722/352213-
dc.description.abstractBackground: Gynaecomastia is a fairly common condition in puberty but is rare in prepubertal boys. While it is necessary to exclude possible endocrinopathay in prepubertal gynaecomastia, medication is an important and potentially reversible cause to consider in new onset gynaecomastia. Isoniazid-induced gynaecomastia has been reported in adult males, but none was reported in the paediatric population and general paediatricians may not be aware of this uncommon side effect. Case presentation: We hereby report a 11-year-old prepubertal boy who developed gynaecomastia while taking anti-tuberculosis drugs. Investigations excluded endocrinopathies. Gynaecomastia subsided 8 weeks after stopping isoniazid. Conclusion: This case is the first paediatric case report describing the association of gynaecomastia with isoniazid use. It is important for general paediatricians to recognize this entity, as prompt diagnosis and cessation of the offending drug can lead to resolution of the problem.-
dc.languageeng-
dc.relation.ispartofBMC Endocrine Disorders-
dc.subjectGynaecomastia-
dc.subjectIsoniazid-
dc.subjectPaediatric-
dc.titleIsoniazid-induced gynaecomastia: report of a paediatric case and review of literature-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1186/s12902-020-00639-9-
dc.identifier.pmid33109161-
dc.identifier.scopuseid_2-s2.0-85094142402-
dc.identifier.volume20-
dc.identifier.issue1-
dc.identifier.spagearticle no. 160-
dc.identifier.epagearticle no. 160-
dc.identifier.eissn1472-6823-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats